China (Mainland)
High Quality Peptide 98% Semaglutide CAS 782487-28-9 ， GLP-1 CAS NO.782487-28-9
- FOB Price: USD: 100.00-100.00 /Kilogram Get Latest Price
- Min.Order: 10 Gram
- Payment Terms: D/P,T/T,
- Available Specifications:
99(1-10000)Kilogram
- Product Details
Keywords
- Semaglutide
- 782487-28-9
- High Quality Peptide
Quick Details
- ProName: High Quality Peptide 98% Semaglutide C...
- CasNo: 782487-28-9
- Appearance: white crystal form
- Application: for research
- DeliveryTime: Immediately
- PackAge: Aluminum foil bag packaging
- Port: SHANGHAI
- ProductionCapacity: 10 Kilogram/Week
- Purity: 99.5%
- Storage: Low temperature aseptic without light
- Transportation: EMS,DHL, FEDEX , HONg Kong express
- LimitNum: 10 Gram
- Moisture Content: 1
- Impurity: 1
Superiority
Details
Product Name: Semaglutide
CAS No. :782487-28-9
Synonyms:semaglutide;AQX10;Rosiptor
Purity: 98% min
Testing Method: HPLC
Appearance: White powder
Semaglutide (USAN; trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. As aglucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production of insulin. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016. FDAapproval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour. It can be used as both injection-type or oral-type drug.
Researchers at the University of Leeds reported in 2017 that it can also be used for the treatment ofobesity. It reduces hunger, food craving and body fat.
Product Name: Semaglutide
CAS No. :782487-28-9
Synonyms:semaglutide;AQX10;Rosiptor
Purity: 98% min
Testing Method: HPLC
Appearance: White powder
Semaglutide (USAN; trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. As aglucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production of insulin. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016. FDAapproval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour. It can be used as both injection-type or oral-type drug.
Researchers at the University of Leeds reported in 2017 that it can also be used for the treatment ofobesity. It reduces hunger, food craving and body fat.